A Review of Novel Formulation Strategies to Enhance Oral Delivery of Zaleplon

Narendar Dudhipala*
Department of Pharmaceutics, Vaagdevi Institute of Pharmaceutical Sciences, Warangal, Telangana-506009, India

Abstract
Zaleplon is a pyrazolopyrimidine which is recommended for the treatment of insomnia and pentyleneetrazole/electroshock-induced convulsions as an effective anticonvulsant which potential acts on the GABA receptor. The poor oral bioavailability of zaleplon (30%) is due to the low solubility which in turn amputates the dissolution of the drug, restricts gastric absorption and first-pass metabolism. It is now withdrawn from the market due to the high dose and inefficient therapeutic activity. This review focuses on the various drug systems of zaleplon such as solid dispersions, self-nanocapsulating, proliposomes and solid lipid nanoparticles to enhance the oral bioavailability.

Keywords: Zaleplon; Oral bioavailability; Dissolution; Proliposomes, Solid lipid nanoparticles

Introduction
Solubility is one of the major limitations in dosage form development of BCS class II and IV pharmaceutical actives. Majority of the new and existing active pharmaceutical ingredients fall in this class possessing low rate of dissolution and/or poor capacity to permeate across the biological membranes amputating their oral bioavailability. Copious techniques like cyclodextrin inclusion complexes; derivatization of the drug by strong or weak electrolytes; particle size reduction of the API using stabilizers and manipulating the drug from its crystalline form to amorphous form using suitable vehicles were investigated by formulation scientists belonging to various research groups to not only improve dissolution of the poorly soluble API but also enhance the bioavailability of lipophilic or hydrophobic drugs. Alternate drug delivery routes like transdermal and intranasal routes were also explored to enhance the bioavailability of drugs with either low solubility or permeability issues [1-9].

Zaleplon, a pyrazolopyrimidine hypnotic drug, is prescribed for the treatment of insomnia and is also a potential anticonvulsant which minimizes the convulsions induced by phenytoin and electroshock [10]. Following administration of zaleplon via oral route the drug is rapidly absorbed, however its absorption is limited due to its poor dissolution owing to its poor aqueous solubility and further delays the onset of action. In conjunction, the bioavailability is only 30% because of extensive first pass metabolism [11]. The major disadvantage of zaleplon is high dose and also causes for occurrence of (typically short-lived) hallucinations. Hence, various approaches have been adopted to enhance the bioavailability of zaleplon by improving its solubility which in turn improves the dissolution rate. These techniques in addition also aided to avoid first-pass metabolism. This review mainly deals with the various approaches mainly solid dispersions, complexation with cyclodextrins; lipid based delivery systems such as proliposomes, nanoemulsifying powders, semisolid dispersions with lipid surfactants and solid lipid nanoparticles to improve the oral bioavailability.

Solid Dispersions of Zaleplon
Initially, Waghmare et al. [12] reported to use solid dispersion technique to enhance the rate of dissolution of zaleplon. The solid dispersions were formulated using various hydrophilic polymers such as Leutrol F68, PVP k30 and PEG 6000 with the aid of solvent evaporation method. The solid-state properties of binary systems were characterized by powder XRD and DSC, with increase in the proportion of the polymer a gradual reduction in the crystalline nature of the drug in the binary systems of zaleplon was observed. The results from the study infer that the zaleplon dissolution can be improved to a greater extent by using solid dispersion techniques like solvent method. In addition the results from these studies conclude that, Solid dosage forms containing zaleplon for oral administration when formulated with poloxamer F68, PVP K30 or PEG 6000 improves the dissolution rate and leads to improvement in the bioavailability of the API to some extent.

Popescu et al. reported the solubility enhancement of zaleplon using complexation technique with cyclodextrin and modified cyclodextrins mainly methyl-β-cyclodextrin, hydroxypropyl-β-cyclodextrin and sulfobutylether-β-cyclodextrin. The solid dispersions are prepared by freeze drying and spray drying methods. Solid state characterization studies reveal the amorphous form of inclusion complex and are the reason for enhancement of solubility of drug. Also reported that solid dispersions made with hydroxypropyl-β-cyclodextrin and sulfobutylether-β-cyclodextrin shows superior solubility of drug than methyl-β-cyclodextrin [13].

Dudhipala et al. reported the a semisolid dispersion (SSD) of zaleplon when formulated using novel self-emulsifying lipid based amphiphilic carriers like TPGS E or Gelucire 44/14, resolve the issues associated with poor solubility of zaleplon [14]. It is quite evident from the phase solubility studies that a linear relationship was found between the drug solubility and concentration of lipid surfactant in aqueous medium which resulted in an A_ type phase diagram. Fusion method when used to formulate zaleplon semisolid dispersions showed a high content uniformity of drug. The microscopic images obtained from the studies using a polarized optical microscopic studies revealed a change

*Corresponding author: Narendar Dudhipala, Associate Professor, Vaagdevi Institute of Pharmaceutical Sciences, Warangal, Telangana-506009, India, Tel: 8099722523; E-mail: dmlns14@gmail.com

Received July 06, 2016; Accepted July 15, 2016; Published July 22, 2016


Copyright: © 2016 Dudhipala N. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
in crystalline form of drug to amorphous or molecular state. The lofter dissolution parameters of zaleplon from SSD over pure crystalline drug obtained from in vitro dissolution studies clearly predict the ability of these lipid surfactants as solubility enhancers. Further, a higher human effective permeability coefficient was observed which encourages the GI absorption of drug from SSD in situ intestinal permeation study was observed when using TPGE E or Gelucire 44/14. The in vivo studies carried out using male wister rats also demonstrated an improvement in the oral bioavailability of zaleplon due to betterment in the availability of the drug at the site of absorption. The various reasons that account for the improvement of bioavailability may also be because of the formation of micelles that improve the effective surface area and further enhance the diffusion through the aqueous filled channels present within the cell membrane structure. Additionally, these self-emulsifying amphiphilic surfactants can either alter the barrier properties of GI membrane by fluidization of membrane or modify the efflux by acting as a P-gp activity modulator and hence, promoting the partitioning of the drugs into the bilayer facilitates the absorption [15,16]. In conclusion from the results of these studies it is evident that the self-emulsifying lipid surfactants act as potential carriers in enhancing the dissolution and oral bioavailability of BCS class II drug, zaleplon.

Self-Nanoemulsifying Delivery of Zaleplon

Karthik et al., 2013 reported the use of lipid emulsion based delivery systems for the enhancement of zaleplon oral bioavailability with the aid of self-nanoemulsifying systems. When formulating the emulsifying systems they first the developed the zaleplon nanoemulsions and converted the nanoemulsions to a powder form by adsorbing it onto different adsorbents like maltodextrin, aerosil 200, pearlitol SD200, neusilin US2. From the preliminary studies it was evident that Neusilin US2 because of its high specific area and unique oil adsorption capacity acts as a better absorbent and was selected as absorbent. A higher predicted permeability coefficient and percentage fraction oral dose was absorbed from the in situ rat intestinal perfusion studies for self-nanoemulsifying powder formulation with respect to control indicates that the capability of the drug to permeate across the intestinal barrier was enhanced. An in vivo pharmacokinetic study was conducted in Wister rats administering a suspension at a control dose of 10 mg/kg. The results from the PK studies revealed an enhancement of ~3 fold in the oral bioavailability upon the administration of nanoemulsions. The results from these studies provide a clear insight on the enhanced dissolution of zaleplon and stability from self-nanoemulsifying lipid systems. The formulations were also characterized using solid state characterization techniques like SEM, DSC, and PXRD studies to investigate the conversion of zaleplon to amorphous or molecular state from its native crystalline form. In situ single-pass perfusion and bioavailability studies were also performed in rats to further confirm the conversion of the crystalline drug to amorphous form. The effective permeability coefficient (Peff) and the rate and extent of absorption from cationic vesicles was significantly enhanced and this enhancement is a clear indication that surface charge plays a major role in enhancing the effective uptake of drugs across the gastrointestinal tract. An enhancement of two- to fivefold be observed upon the use of proliposomes and this enhancement in bioavailability clearly indicates that proliposomes are potential carriers that enhance the oral bioavailability of zaleplon when administered via oral route [18-20].

Conclusion

Multiple formulation approaches to improve the bioavailability of the poorly soluble drugs are discussed in this article. Similar approaches using formulation of solid dispersions via spray drying, freeze drying or techniques like self nanoemulsifying systems or proliposomal systems can be considered to be potential strategies to enhance the solubility of various class II or class IV drugs.

References